We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed at $188.42 in the latest trading session, marking a +2.74% move from the prior day. The stock's change was more than the S&P 500's daily loss of 1.67%. Meanwhile, the Dow experienced a drop of 1.73%, and the technology-dominated Nasdaq saw a decrease of 2.15%.
Coming into today, shares of the pharmaceutical had lost 10.09% in the past month. In that same time, the Medical sector lost 7.36%, while the S&P 500 lost 6.15%.
The investment community will be closely monitoring the performance of Astrazeneca in its forthcoming earnings report. The company's upcoming EPS is projected at $2.5, signifying a 0.81% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $14.81 billion, showing a 9.02% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.31 per share and a revenue of $62.86 billion, signifying shifts of +12.55% and +7.01%, respectively, from the last year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 0.31% rise in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #3 (Hold).
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 17.78. This indicates a premium in contrast to its industry's Forward P/E of 17.76.
One should further note that AZN currently holds a PEG ratio of 1.38. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.52 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 148, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
Astrazeneca (AZN - Free Report) closed at $188.42 in the latest trading session, marking a +2.74% move from the prior day. The stock's change was more than the S&P 500's daily loss of 1.67%. Meanwhile, the Dow experienced a drop of 1.73%, and the technology-dominated Nasdaq saw a decrease of 2.15%.
Coming into today, shares of the pharmaceutical had lost 10.09% in the past month. In that same time, the Medical sector lost 7.36%, while the S&P 500 lost 6.15%.
The investment community will be closely monitoring the performance of Astrazeneca in its forthcoming earnings report. The company's upcoming EPS is projected at $2.5, signifying a 0.81% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $14.81 billion, showing a 9.02% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.31 per share and a revenue of $62.86 billion, signifying shifts of +12.55% and +7.01%, respectively, from the last year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 0.31% rise in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #3 (Hold).
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 17.78. This indicates a premium in contrast to its industry's Forward P/E of 17.76.
One should further note that AZN currently holds a PEG ratio of 1.38. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.52 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 148, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.